This company has a approved drug, current sales of $170 million, $116 million in cash and a 31% short position. I would say, that at $90 it was looking rich, but at $33? This is ridiculous, this could be the buy of the decade.
What is your point? Why would you use a trailing 12 month revenue? Why would look backwards in terms of sales? That shows your ignorance. Growth of stocks are not calculated by what they did in the past, it was is to come in the future, that is why it is called growth. By they way, 1Q was at $27 million 36% of that figure in 1 quarter. Also, the company provides sales guidance of $180-$200 million for the year as do several analysts. They also have newly expanded sales force and are seeing meaningful script trends.
The company needs new management. The cNBC corrective action video still hasn't posted (to clean-up what Marc Beer said), needed marketing fixes have not been addressed and now the largest European market (Germany) will not allow Juxtapid sales because $AEGR management was so arrogant to believe they didn't need to do the required comparative study. I believe in Juxtapid, but not it's leadership. I'd almost guess these bad moves have been made on purpose, so that the company was more of a buyout target, allowing them to walk away quickly with fat pockets. CEO Marc Beer must go.